in which $X_1 \ldots X_n$ represents a sequence of 3-5 amino acids, wherein the amino acid sequence $X_1 \ldots X_n$ is selected from the group comprising the amino acid sequences VGG, VLSG, ATG, VSG, DSG, VVSG, ALAG, APSG and VGR, or

[(b) a nucleotide sequence which codes for an amino acid sequence which is at least 80% identical with the amino acid sequence from (a), or]

(b) [(c)] a nucleotide sequence which codes for an amino acid sequence with an equivalent recognition specificity, as achieved with a T cell receptor comprising a CDR3 region with the amino acid sequence of SEQ ID NO. 23, for the peptide component of the T cell receptor ligands.

Claim 4, line 1, delete "1" and substitute --2-- therefore.

Claim 5. (Amended) Vector,

wherein

it contains at least one copy of a nucleic acid as claimed in claim 2 or 4. [one of the claims 1 to 4.]

Claim 6. (Amended) Cell,

wherein

it expresses a nucleic acid as claimed in claim 2 or 4. [one of the claims 1 to 4.]

Claim 7. (Amended) Cell,

wherein

it is transformed with a nucleic acid as claimed in claim 2 or 4 [one of the claims 1 to 4] or with a vector as claimed in claim 5.

Claim 26. (Amended) Pharmaceutical composition which contains as active component a nucleic acid as claimed in one of the claims 2 or 4, [1 to 4 or 10 to 14, a polypeptide as claimed in one of the claims 8, 9 or 18 to 23, a peptide ligand against the polypeptide, an antibody as claimed in claims 23 or 24] or a cell as claimed in claim 6 or 7 [6, 7, 16, 17 or 25] optionally together with other active components as well as common pharmaceutical auxiliary agents, additives or carrier substances.